PMID- 38267451
OWN - NLM
STAT- MEDLINE
DCOM- 20240126
LR  - 20240206
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 14
IP  - 1
DP  - 2024 Jan 24
TI  - Impact of metformin on cardiovascular and kidney outcome based on kidney function 
      status in type 2 diabetic patients: a multicentric, retrospective cohort study.
PG  - 2081
LID - 10.1038/s41598-024-52078-4 [doi]
LID - 2081
AB  - Metformin is the primary treatment for type 2 diabetes mellitus (T2DM) due to its 
      effectiveness in improving clinical outcomes in patients with preserved renal 
      function, however, the evidence on the effectiveness of metformin in various 
      renal functions is lacking. We performed a retrospective, multicenter, 
      observational study used data of patients with T2DM obtained from three tertiary 
      hospitals' databases. Patients given metformin within run-in periods and with at 
      least one additional prescription formed the metformin cohort. A control cohort 
      comprised those prescribed oral hypoglycemic agents other than metformin and 
      never subsequently received a metformin prescription within observation period. 
      For patients without diabetic nephropathy (DN), the outcomes included events of 
      DN, major adverse cardiovascular events (MACE), and major adverse kidney events 
      (MAKE). After 1:1 propensity matching, 1994 individuals each were selected for 
      the metformin and control cohorts among T2DM patients without baseline DN. The 
      incidence rate ratios (IRR) for DN, MACEs, and MAKEs between cohorts were 1.06 
      (95% CI 0.96-1.17), 0.76 (0.64-0.92), and 0.45 (0.33-0.62), respectively. In 
      cohorts with renal function of CKD 3A, 3B, and 4, summarized IRRs of MACEs and 
      MAKEs were 0.70 (0.57-0.87) and 0.39 (0.35-0.43) in CKD 3A, 0.83 (0.74-0.93) and 
      0.44 (0.40-0.48) in CKD 3B, and 0.71 (0.60-0.85) and 0.45 (0.39-0.51) in CKD 4. 
      Our research indicates that metformin use in T2DM patients across various renal 
      functions consistently correlates with a decreased risk of overt DN, MACE, and 
      MAKE.
CI  - (c) 2024. The Author(s).
FAU - Yi, Yongjin
AU  - Yi Y
AD  - Department of Internal Medicine, Dankook University College of Medicine, 
      Cheonan-si, Republic of Korea.
FAU - Kwon, Eun-Jeong
AU  - Kwon EJ
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Yun, Giae
AU  - Yun G
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Park, Seokwoo
AU  - Park S
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Jeong, Jong Cheol
AU  - Jeong JC
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Na, Ki Young
AU  - Na KY
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Chin, Ho Jun
AU  - Chin HJ
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Yoo, Sooyoung
AU  - Yoo S
AD  - Healthcare ICT Research Center, Seoul National University Bundang Hospital, 
      Seongnam-si, Republic of Korea.
FAU - Kim, Seok
AU  - Kim S
AD  - Healthcare ICT Research Center, Seoul National University Bundang Hospital, 
      Seongnam-si, Republic of Korea.
FAU - Oh, Tae Jung
AU  - Oh TJ
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea.
FAU - Kim, Sejoong
AU  - Kim S
AUID- ORCID: 0000-0002-7238-9962
AD  - Division of Nephology, Department of Internal Medicine, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea. sejoong2@snu.ac.kr.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Republic of Korea. sejoong2@snu.ac.kr.
AD  - Center for Artificial Intelligence in Healthcare, Seoul National University 
      Bundang Hospital, Seongnam-si, Republic of Korea. sejoong2@snu.ac.kr.
LA  - eng
GR  - Young Investigator Research Grant 2020/Korean Society of Nephrology/
GR  - RS-2023-00220408/National Research Foundation of Korea/
GR  - 16-2018-007/Seoul National University Bundang Hospital,South Korea/
GR  - 16-2018-007/Seoul National University Bundang Hospital,South Korea/
GR  - 16-2018-007/Seoul National University Bundang Hospital,South Korea/
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20240124
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Metformin/therapeutic use
MH  - Kidney
MH  - *Diabetic Nephropathies/drug therapy
MH  - *Myristica
MH  - *Renal Insufficiency, Chronic
PMC - PMC10808543
COIS- The authors declare no competing interests.
EDAT- 2024/01/25 00:42
MHDA- 2024/01/26 06:43
PMCR- 2024/01/24
CRDT- 2024/01/24 23:16
PHST- 2023/10/17 00:00 [received]
PHST- 2024/01/12 00:00 [accepted]
PHST- 2024/01/26 06:43 [medline]
PHST- 2024/01/25 00:42 [pubmed]
PHST- 2024/01/24 23:16 [entrez]
PHST- 2024/01/24 00:00 [pmc-release]
AID - 10.1038/s41598-024-52078-4 [pii]
AID - 52078 [pii]
AID - 10.1038/s41598-024-52078-4 [doi]
PST - epublish
SO  - Sci Rep. 2024 Jan 24;14(1):2081. doi: 10.1038/s41598-024-52078-4.